Up to 40% of cancers may not present clinically

Seattle-Despite the way it was portrayed in some of the lay media, the authors of a recent study on the "overdiagnosis" of prostate cancer insist their work should not be construed as hostile to the practice of PSA screening. In fact, says one investigator, results of the study paint an overall favorable picture of screening.

Related Videos

Related Content

Advertisement

March 11th 2025

Study progresses of sunobinop for interstitial cystitis/bladder pain syndrome

Hannah Clarke

"The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD.

March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 10th 2025

Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC

Hannah Clarke

"Considering that almost all patients in the combined treatment group achieved testosterone recovery at 1 year, the results support that this short term (intermittent) combined approach is an optimal option in selected patients with metachronous oligorecurrent hormone-sensitive prostate cancer," the authors wrote.

February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 6th 2025

64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer

Hannah Clarke

The detection rate ranged from 44% to 58% on day 0 and 58% to 80% on day 1.

March 6th 2025

Identifying unique therapeutic targets for chromophobe kidney cancer

David A. Braun, MD, PhD Hannah Clarke

“What we hope overall is that this is a biological study that might inform therapeutic development for this disease,” says David A. Braun, MD, PhD.

Related Content

Advertisement

March 11th 2025

Study progresses of sunobinop for interstitial cystitis/bladder pain syndrome

Hannah Clarke

"The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD.

March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 10th 2025

Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC

Hannah Clarke

"Considering that almost all patients in the combined treatment group achieved testosterone recovery at 1 year, the results support that this short term (intermittent) combined approach is an optimal option in selected patients with metachronous oligorecurrent hormone-sensitive prostate cancer," the authors wrote.

February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 6th 2025

64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer

Hannah Clarke

The detection rate ranged from 44% to 58% on day 0 and 58% to 80% on day 1.

March 6th 2025

Identifying unique therapeutic targets for chromophobe kidney cancer

David A. Braun, MD, PhD Hannah Clarke

“What we hope overall is that this is a biological study that might inform therapeutic development for this disease,” says David A. Braun, MD, PhD.